Gland Pharma Ltd
GLANDGland Pharma Ltd
GLANDPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
42.90 | 3.40 | 1.11% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast from 9 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,772.41 | 3,597.66 | 4,624.65 | 3,865.06 | 5,834.96 | 6,080.78 | ||||||
Raw Materials | 1,108.93 | 1,765.36 | 2,072.53 | 1,732.34 | 2,045.20 | 4,613.66 | ||||||
Power & Fuel Cost | 78.50 | 74.59 | 95.05 | 124.84 | 229.99 | |||||||
Employee Cost | 277.66 | 311.36 | 338.57 | 403.26 | 1,256.89 | |||||||
Selling & Administrative Expenses | 98.54 | 128.48 | 177.92 | 187.93 | 286.86 | |||||||
Operating & Other expenses | 114.15 | -119.14 | 206.49 | 207.92 | 512.71 | |||||||
EBITDA | 1,094.63 | 1,437.01 | 1,734.09 | 1,208.77 | 1,503.31 | 1,467.12 | ||||||
Depreciation/Amortization | 94.59 | 98.78 | 110.30 | 146.74 | 344.57 | 383.74 | ||||||
PBIT | 1,000.04 | 1,338.23 | 1,623.79 | 1,062.03 | 1,158.74 | 1,083.38 | ||||||
Interest & Other Items | 7.18 | 3.41 | 5.24 | 7.45 | 26.20 | 26.97 | ||||||
PBT | 992.86 | 1,334.82 | 1,618.55 | 1,054.58 | 1,132.54 | 1,056.41 | ||||||
Taxes & Other Items | 220.01 | 337.85 | 406.89 | 273.54 | 360.08 | 364.84 | ||||||
Net Income | 772.85 | 996.97 | 1,211.66 | 781.04 | 772.46 | 691.57 | ||||||
EPS | 49.88 | 62.60 | 73.91 | 47.48 | 46.90 | 41.99 | ||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 20.00 | ||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.48 |
Company Updates
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Gland Pharma Ltd | 38.41 | 3.40 | 1.11% |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare GLAND with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 2.41%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 2.30%
Top 5 Mutual Funds holding Gland Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.0896% | Percentage of the fund’s portfolio invested in the stock 1.22% | Change in the portfolio weight of the stock over the last 3 months -0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/79 (-7) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.0520% | Percentage of the fund’s portfolio invested in the stock 1.60% | Change in the portfolio weight of the stock over the last 3 months -0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/105 (-3) |
SBI Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.6988% | Percentage of the fund’s portfolio invested in the stock 1.72% | Change in the portfolio weight of the stock over the last 3 months 0.41% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/85 (+20) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹20.00
Ex DateEx Date
Aug 16, 2024
Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1809.85, up 1.67% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Gland Pharma Ltd has added around 12.35% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 1.11 lakh shares today, compared to the daily average of 4.86 lakh shares in last one month.The PE of the stock is 26.58 based on TTM earnings ending September 24.Powered by Capital Market - Live
The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan, Latanoprost Ophthalmic Solution held by UPJOHN US 2 LLC. This product is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension. The drug maker expects to launch this product through its marketing partners in FY25. According to IQVIA, the product had US sales of approximately $111.6 million for the twelve months ending December 2023. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live
Chemplast Sanmar Ltd, Hatsun Agro Product Ltd, ABB India Ltd, Bata India Ltd are among the other stocks to see a surge in volumes on BSE today, 05 November 2024.Gland Pharma Ltd saw volume of 47247 shares by 10:47 IST on BSE, a 10.69 fold spurt over two-week average daily volume of 4421 shares. The stock increased 9.75% to Rs.1,766.80. Volumes stood at 6858 shares in the last session.Chemplast Sanmar Ltd recorded volume of 36259 shares by 10:47 IST on BSE, a 5.59 times surge over two-week average daily volume of 6484 shares. The stock gained 4.70% to Rs.497.00. Volumes stood at 7142 shares in the last session.Hatsun Agro Product Ltd witnessed volume of 12872 shares by 10:47 IST on BSE, a 4.76 times surge over two-week average daily volume of 2704 shares. The stock increased 9.17% to Rs.1,160.15. Volumes stood at 9414 shares in the last session.ABB India Ltd recorded volume of 37866 shares by 10:47 IST on BSE, a 4.45 times surge over two-week average daily volume of 8510 shares. The stock lost 3.97% to Rs.7,069.90. Volumes stood at 9507 shares in the last session.Bata India Ltd notched up volume of 43257 shares by 10:47 IST on BSE, a 3.69 fold spurt over two-week average daily volume of 11733 shares. The stock rose 0.59% to Rs.1,344.75. Volumes stood at 15468 shares in the last session.Powered by Capital Market - Live
On consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore on 2.36% to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. Profit before tax (PBT) stood at Rs 256.78 crore, down 11.42% as compared with Rs 289.89 crore in second quarter of FY24. For Q2 of FY25, EBITDA was Rs 296.1 crore, registering de-growth of 8%. EBITDA margin reduced from 21% to 23% during the quarter. Revenue from US market stood at Rs 754.7 crore (up 3% YoY), revenue Europe was at Rs 245.9 crore (down 1% YoY), Canada, Australia and New Zealand stood at Rs 51.5 crore (up 45% YoY) while revenue from India was at Rs 87.4 crore and Rest of the world was at Rs 266.3 crore during the period under review. Total capex incurred during the quarter was Rs 103.7 crore. R&D expenses stood at Rs 49.3 crore in Q2 of FY25, (4.6% of revenue). Cenexi's gross profit shed 15% YoY to Rs 234.7 crore and revenue from operations decreased 5% YoY to Rs 339.9 crore during the quarter. On outlook front, the company said that despite the near-term headwinds, it continued to strive to achieve short-term outlook: a positive EBITDA for Q4 of FY25. It maintains goal of a positive EBITDA for the next fiscal year, driven by an increase in revenue above the '200 million threshold. Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, 'We had a good first half of 2025 and are on course to achieve our outcomes for the full year. This quarter, we reported Rs 14,058 million in revenue and Rs 2,961 million in EBITDA, representing a 21% EBITDA margin. Although our overall EBITDA margin was affected by Cenexi, our base business maintained a steady 34% EBITDA margin. Our core regulated markets, particularly the United States, continue to perform well. Our overall performance is in line with expectations. Looking ahead, we remain focused on our strategic priorities, which include entering new markets and building a solid foundation for future growth.' Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.Powered by Capital Market - Live
Net profit of Gland Pharma declined 15.74% to Rs 163.53 crore in the quarter ended September 2024 as against Rs 194.08 crore during the previous quarter ended September 2023. Sales rose 2.36% to Rs 1405.83 crore in the quarter ended September 2024 as against Rs 1373.42 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1405.831373.42 2 OPM %21.1323.60 - PBDT350.60371.19 -6 PBT256.78289.89 -11 NP163.53194.08 -16 Powered by Capital Market - Live
Gland Pharma will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live
Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1809, down 1.76% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Gland Pharma Ltd has lost around 6.26% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 77964 shares today, compared to the daily average of 3.85 lakh shares in last one month.The PE of the stock is 28.14 based on TTM earnings ending June 24.Powered by Capital Market - Live
Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1936.35, up 1.59% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.02% on the day, quoting at 24856.05. The Sensex is at 81295.07, up 0.14%. Gland Pharma Ltd has slipped around 4.99% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has slipped around 3.48% in last one month and is currently quoting at 23043.4, down 0.28% on the day. The volume in the stock stood at 3.79 lakh shares today, compared to the daily average of 4.18 lakh shares in last one month.The PE of the stock is 29.1 based on TTM earnings ending June 24.Powered by Capital Market - Live
Revenue from operations jumped 15.97% YoY to Rs 1,401.70 crore in Q1 FY25. Profit before tax (PBT) stood at Rs 218.24 crore, down 16.47% as compared with Rs 261.26 crore in Q1 FY24. EBITDA fell to Rs 265.4 crore during the quarter as compared with Rs 298.2 crore in Q1 FY23, registering de-growth of 11%. EBITDA margin reduced from 25% to 19% during the quarter. Revenue from US market stood at Rs 762.8 crore (up 27% YoY), revenue Europe was at Rs 256.6 crore (up 15% YoY), Canada, Australia and New Zealand stood at Rs 44.7 crore (up 72% YoY) while revenue from India was at Rs 52.7 crore (down 19% YoY) and Rest of the world was at Rs 284.9 crore (down 3% YoY) during the period under review. Total capex incurred during the quarter was Rs 63.7 crore. R&D expenses stood at Rs 48.9 crore in Q1 FY25, (5% of revenue). Cenexi's gross profit jumped 24% to Rs 302.6 crore during the quarter as comapred with Rs 243.6 crore in Q1 FY24. Revenue from operations increased 21% YoY to Rs 388.3 crore during the quarter. On outlook front, the company said that In Q2 FY25 Lower activity levels are expected due to the European holiday season and planned summer maintenance shutdowns. The Fontenay plant will have an extended 3-week shutdown for new ampoule line installation. It expects positive EBITDA for Q4 of this fiscal year and a positive EBITDA for the next fiscal year, driven by increased revenue exceeding the '200 million threshold. Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, 'We reached Rs 1,401.7 crore in total revenue, a 16% increase from Q1FY24. This growth aligns with our projections and is primarily driven by the US market, which saw a 27% revenue increase led by existing and certain new products. Our base business EBITDA margins were at 29%, and consolidated EBITDA margins for the quarter were 19%, mainly affected by Cenexi. We're confident in our ability to meet our fiscal year goals and are excited about the growing opportunities and even stronger results expected in the coming quarters.' Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.Powered by Capital Market - Live
Net profit of Gland Pharma declined 25.94% to Rs 143.76 crore in the quarter ended June 2024 as against Rs 194.10 crore during the previous quarter ended June 2023. Sales rose 15.97% to Rs 1401.71 crore in the quarter ended June 2024 as against Rs 1208.69 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1401.711208.69 16 OPM %18.8624.32 - PBDT310.21326.58 -5 PBT218.25261.27 -16 NP143.76194.10 -26 Powered by Capital Market - Live
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 6.02%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant